1.
Eisenstein KA. Infantile hemangiomas: a review and future opportunities. Mo Med. 2023;120(1):49-52.
2.
Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150(3):291-294. doi:10.1016/j.jpeds.2006.12.003
3.
Cazeau C, Blei F, Gonzáles Hermosa MDRF, et al. Burden of infantile hemangioma on family: an international observational cross-sectional study. Pediatr Dermatol. 2017;34(3):295-302. doi:10.1111/pde.13133
4.
Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas. BMJ. 2022;378:e068734. doi:10.1136/bmj-2021-068734
5.
Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1): e20183475. doi:10.1542/peds.2018-3475
6.
Broeks IJ, Hermans DJ, Dassel AC, van der Vleuten CJ, van Beynum IM. Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature. Int J Pediatr Otorhinolaryngol. 2013; 77(11):1791-1800. doi:10.1016/j.ijporl.2013.08.011
7.
Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-140. doi:10.1542/peds.2012-1691
8.
Nazemian S, Sharif S, Childers ELB. Infantile hemangioma: a common lesion in a vulnerable population. Int J Environ Res Public Health. 2023; 20(8):5585.doi:10.3390/ijerph20085585
9.
Jacobs AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med. 1957;86(1):8-10.
10.
Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas. BMJ. 2022;378:e068734. doi:10.1136/bmj-2021-068734
11.
Gnarra M, Behr G, Kitajewski A, et al. History of the infantile hepatic hemangioma: from imaging to generating a differential diagnosis. World J Clin Pediatr. 2016;5(3):273-280. doi:10.5409/wjcp.v5.i3.273
12.
Tiemann L, Hein S. Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls. J Pediatr Pharmacol Ther. 2020;25(7):586-599. doi:10.5863/1551-6776-25.7.586
13.
McGee P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital. Ulster Med J. 2013;82(1):16-20.
14.
Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):e423-e431. doi: 10.1542/peds.2008-3458
15.
Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma. Br J Dermatol. 2013;169(1):12-19. doi:10.1111/bjd.12435
16.
Phung TL, Hochman M. Pathogenesis of infantile hemangioma. Facial Plast Surg. 2012;28(6):554-562. doi:10.1055/s-0032-1329930
17.
Eroglu N, Sen HS, Kar YD, Pektas A, Eker I. Can propranolol affect platelet indices in infantile hemangioma? J Pediatr Hematol Oncol. 2023;45(7):e899-e903. doi:10.1097/MPH.0000000000002683
18.
Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood. 1977;49(2):185-196. doi:10.1182/blood.V49.2.185.185
19.
Ring ME, Corrigan JJ Jr, Fenster PE. Antiplatelet effects of oral diltiazem, propranolol, and their combination. Br J Clin Pharmacol. 1987;24(5):615-620. doi:10.1111/j.1365-2125.1987.tb03220.x
20.
Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012;44(8):805-816. doi:10.3109/ 07853890.2011.653391
21.
Şen HS, Yalçın B, Canpınar H, Ocak S, Akyüz C. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol. Turk J Pediatr. 2020;62(6):979-985. doi:10.24953/turkjped.2020.06.009